versión imprimible
 
 

BCMA Targeted Therapies

Evvnt Promotion / evvnt
-
21.06.2021 - 23.06.2021  Online
Time: 09:00 - 16:00
 
Temas de la conferencia
Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.
Organizador profesional (PCO)
Hanson Wade
Observaciones
Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron and more.
 

Información e inscripción:

https://go.evvnt.com/727512-2?pid=4832
Mr. Customer Service
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
USD 1799.0 - USD 3237.0
Los participantes esperaban
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Helix - Forschung & Beratung WienÖsterreichische Gesellschaft für Public HealthSwiss Tropical and Public Health InstituteCenter of ExcellenceÄrztekammer für WienÄrzte der WeltHilfswerk AustriaEuropean Health Forum Gastein